Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Innomedica

Next Previous
Drug Profile

Doxorubicin liposomal - Innomedica

Alternative Names: Talidox; Targeted liposomal doxorubicin; TLD; TLD-1

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoMedica
  • Developer InnoMedica; Swiss Group for Clinical Cancer Research
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 03 Mar 2025 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the European Society for Medical Oncology Targeted Anticancer Therapies Congress (ESMO TAT-2025)
  • 10 Sep 2024 Phase-I/II clinical trials in Breast cancer (IV) (Innomedica pipeline, September 2024)
  • 10 Sep 2024 Phase-I/II clinical trials in Ovarian cancer (IV) (Innomedica pipeline, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top